Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleGPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06196294 - Phase 1Taking peopleGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198546 - Phase 2/3Taking peopleTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Where
- Guanzhou
- Age
- 18 years and over
- People
- 200
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03755739 - Phase 2Taking peopleTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Where
- Guangzhou
- Age
- 18 years to 85 years
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04803318 - Phase 1Taking peopleEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Where
- Guangzhou
- Age
- 18 years to 85 years
- People
- 40
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04842812 - Phase 1/2Taking peopleTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05187338 - Phase 1Taking peoplePalliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Zhiyong Huang
See details and how to joinNCT06470256 - No phaseNot yet taking people in ChinaCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Where
- Foshan, Guangzhou, Guanzhou
- Age
- 18 years to 75 years
- People
- 152
- Run by
- Zhujiang Hospital
See details and how to joinNCT06449846 - No phaseNot yet taking people in ChinaCombining Chemoradiotherapy With Sintilimab in First-Line ICC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 19
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06447454 - Phase 1Taking peopleITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
- Where
- Guangzhou, Luzhou
- Age
- 18 years to 80 years
- People
- 90
- Run by
- Institute of Automation, Chinese Academy of Sciences
See details and how to joinNCT06204835 - Phase 1/2Not yet taking people in ChinaFOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 62
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06409637 - Phase 2Taking peopleCadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Where
- Changsha
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT06406634 - Phase 4Taking peoplePrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Chen Xiaoping
See details and how to joinNCT06311929 - Phase 2Taking peopleSintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 23
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06397222 - Phase 3Not yet taking people in ChinaPostoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 360
- Run by
- Tongji Hospital
See details and how to joinNCT06089369 - Phase 2Taking peoplePhase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
- Where
- Beijing
- Age
- 18 years to 90 years
- People
- 30
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06389422 - Phase 3Taking peopleLenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 196
- Run by
- Wen Tianfu
See details and how to joinNCT05738616 - Phase 2Taking peopleChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 40
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06280508 - Phase 2Taking peopleAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Where
- Beijing
- Age
- 18 years and over
- People
- 111
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06360042 - Phase 2Taking peoplePerioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
- Where
- Jinan
- Age
- 18 years and over
- People
- 20
- Run by
- Lei ZHAO
See details and how to joinNCT06296563 - Phase 2Taking peopleA Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
- Where
- Fuzhou
- Age
- 18 years to 80 years
- People
- 57
- Run by
- Fujian Medical University
See details and how to joinNCT06363825 - Phase 1Taking peopleCombination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06363006 - No phaseTaking peopleImmunotherapy for Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years and over
- People
- 11,000
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06241326 - Phase 1/2Taking peopleOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Where
- Beijing, Changchun, Changsha, Chengdu, Hangzhou, Lishui, Shanghai
- Age
- 18 years to 70 years
- People
- 105
- Run by
- OriCell Therapeutics Co., Ltd.
See details and how to joinNCT05652920 - Phase 2Taking peopleCadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06215651